

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22314-1450 www.uspto.gov

RE: EYLEA® (aflibercept)

Docket No.: FDA-2012-E-0489

Frank Cottingham
Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Rd.
Tarrytown, NY 10591-6707

In Re: Patent Term Extension
Application for
U.S. Patent No. 7,070,959

MAY 2 5 2016

Dear Mr. Cottingham:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 7,070,959 for a period of 1,119 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to patent expiration dates as necessary.

Inquiries regarding this communication should be directed to the undersigned by telephone at (571) 272-7755, or by e-mail at mary.till@uspto.gov.

/Mary C. Till

Senior Legal Advisor

Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Food and Drug Administration CDER, Office of Regulatory Policy

10903 New Hampshire Avenue,

Bldg. 51 Room 6250

Silver Spring MD 20993-0002

Attention: Beverly Friedman

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM (12)UNDER 35 U.S.C. § 156

7,070,959 PATENT NO. (68)

July 4, 2006 (45)**ISSUED**

Nicholas J. Papadopoulos et al. (75) INVENTOR

Regeneron Pharmaceuticals Inc. (73) PATENT OWNER


(95) PRODUCT EYLEA® (aflibercept)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 7,070,959 based upon the regulatory review of the product EYLEA® (aflibercept) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

1,119 days (94)

from May 23, 2020, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156.

I have caused the seal of the United States Patent and



Michelle K. Lee

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office



Michelle K. Lee